|
Objective: seminoma (seminoma) is an insidious onset, dangerous disease, testicular cancer. It originated in the primordial germ cells, is the most common malignant tumor of the testis, once the disease, if not treated, the mortality rate is high. Therefore, early detection and treatment is the key to cure seminoma. As with other malignancies, the formation and development of seminoma is a multi-step, multi-gene combined result. Tumorigenesis learn that an important part of the process of tumorigenesis is all kinds of gene expression changes, the intracellular activation of the proto-oncogene overexpression and tumor suppressor gene inactivation. Therefore, Oct4, PLAP, VEGF, p53 gene, we studied the molecular level the seminoma malignant process oncogenes, tumor suppressor gene expression changes, for early diagnosis of seminoma and treatment fine The seminoma provide on the basis of molecular biology. Methods: Immunohistochemical SP method, detection OCT4, PLAP, VEGF, p53 gene expression in 38 cases of seminoma tumors, the application of saturated phenol - chloroform extraction 11 cases of paraffin tissue DNA, application of PCR-SSCP method, detection of p53 seminoma mutations and deletions. Results: (1) Oct4 seminoma positive expression rate of 100%, not expressed in normal testicular tissue; PLAP in seminoma positive expression rate of 89.47%, in normal testicular tissue in the same expression. While under the microscope, the Oct4 expression slices background color is very low; while the the PLAP expression of many slices, the background color is heavier. (2) VEGF seminoma clinical stage Ⅰ the positive expression rate was 33.33%, positive expression rate of 90.91% of Phase II, Phase III positive expression rate of 100%. Phase I and II of the comparison between the groups I and III of a statistically significant difference (p lt; 0.01), no statistically significant difference (p gt; 0.05) between II and III; in 10 cases of normal testicular organizations, two cases of weak positive and negative. p53 in seminoma clinical stage Ⅰ positive expression rate of 93.33%, II and III of the expression rate was 54.55% and 50%, respectively. Phase I and II of Phase I and III between the two groups were significantly different (p lt; 0.05), no statistical comparison between the II and III of. Difference (p gt; 0.05); 10 cases of normal testicular tissue were negative. (3) the expression of VEGF and p53 genes in seminoma no correlation (r = 0.183, p gt; 0.05) (4) p53 the seminoma mutation, the mutation rate was 45.45%. Conclusion: 1, Oct4 in seminoma were expressed in, is an excellent marker gene diagnosis of seminoma, compared with PLAP more sensitive. Progress with the clinical stage seminoma, VEGF positive expression rate is getting higher and higher, prompted the VEGF plays an important role in the occurrence and development of seminoma; p53 in the regulation spermatogonia tumor development process play an important role, mainly in the early clinical stage; seminoma, there is no correlation of p53 and VEGF. 3, p53 in seminoma occurrence and development process, there are abnormal gene expression.
|